Severe bradycardia: An unreported adverse infusion-associated reaction (IAR) with alemtuzumab
E Nerrant1, E Thouvenot2, G Castelnovo1
1CHU de Nîmes, Department of Neurology, 9, place du Pr Robert Debré, Nîmes Cedex 9, 30029, France.
No abstract available in PubMed .
More Related Videos
08:56Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
Published on: September 24, 2021
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
Related Concept Videos
Decreased pulse rate
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
Cardiac Catheterization IV: Nursing Management
Dysrhythmias IV: Characteristics of Bradyarrhythmias
Cardiopulmonary Resuscitation IV: Pharmacological Management
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
